VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ARDXArdelyx, Inc.
$5.55$1.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksARDXCash Flow

Ardelyx, Inc. (ARDX) Cash Flow Statement

14Y historyFree accessUpdated daily

Free cash flow remains persistently negative, with a $32.3 million deficit in 2026Q1 exacerbated by $14.2 million in stock-based compensation that obscures the true magnitude of cash burn.

ARDX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash from Operations-36.26M-42.48M-44.81M-89.72M-70.04M-152.55M-81.44M-76.48M-70.27M-65.19M-92.53M-71.84M13.4M1.81M21.98M
Operating CF Margin %--10.43%-13.43%-72.09%-134.29%-1510.85%-1075.62%-1448.29%-2695.59%-155.21%-385.14%-299.01%42.36%6.26%406.28%
Operating CF Growth %71.95%5.19%50.06%-28.09%54.08%-87.33%-6.47%-8.84%-7.8%29.55%-28.81%-636.24%639.76%-91.76%-
Net Income-58.06M-61.6M-39.14M-66.07M-67.21M-158.16M-94.31M-94.94M-91.3M-64.34M-112.39M-29.62M-3.21M-6.56M-9.79M
Depreciation & Amortization3.37M3.06M2.06M1.29M1.14M1.44M1.82M2.5M2.68M2.64M1.29M829K302K592K675K
Stock-Based Compensation38.59M48.96M37.38M13.53M10.75M12.04M10.58M9.94M9.23M9.59M5.32M2.63M1.69M352K473K
Deferred Taxes00000-190K315K-262K-1.02M11K-86K65K000
Other Non-Cash Items8.06M-1.55M4.05M4.91M4.84M4.25M3.37M3.3M792K567K540K458K1.59M3.51M950K
Working Capital Changes-28.23M-31.35M-49.17M-43.39M-19.57M-11.92M-3.21M2.98M9.35M-13.66M12.79M-46.2M13.02M3.92M29.67M
Change in Receivables-36.37M-14.14M-35.67M-14.3M-7.23M-502K750K85K10.71M-10.8M02.58M3.85M-3.36M-3.07M
Change in Inventory-22.15M-31.92M-41.7M-21.14M-28.35M-10.37M-750K-3.41M1.88M-1.9M0-2.08M743K-730K-578K
Change in Payables14.47M3.23M4.86M279K6.58M-1.35M3.44M39K-2.73M-1.03M2.15M-371K831K1.14M-105K
Cash from Investing-21.8M-8.96M-18.32M-131.25M18.41M50.95M-31.44M23.37M-29.89M65.29M-131.08M-3.45M-1.86M-278K-128K
Capital Expenditures-1.24M-1.49M-1.01M-344K-55K-1.87M-324K-325K-311K-2.35M-4.87M-3.45M-1.86M-278K-128K
CapEx % of Revenue0.29%0.37%0.3%0.28%0.11%18.49%4.28%6.15%11.93%5.61%20.25%14.38%5.87%0.96%2.37%
Acquisitions00000-52.81M31.44M-23.7M0000000
Investments---------------
Other Investing00001.8M52.81M-31.44M23.7M-29.58M67.64M-126.21M0000
Cash from Financing58.47M54.51M106.59M146.29M75.34M83M22.78M155.48M103.55M685K191.2M75.01M61.31M-1K270K
Debt Issued (Net)48.67M48.67M99.45M22.39M-6.07M-19.44M-125K049.29M000000
Equity Issued (Net)9.8M5.84M8.14M119.24M71.63M101.15M21.05M154.9M53.77M0190.57M74.32M61.24M-1K-20K
Dividends Paid000000000000000
Share Repurchases000000000000-2K-2K-20K
Other Financing00-1M4.67M9.78M1.3M1.85M574K491K685K631K689K69K0290K
Net Change in Cash401K3.07M43.46M-74.67M23.71M-18.6M-90.1M102.36M3.38M785K-32.41M-282K72.85M1.53M22.12M
Free Cash Flow-37.5M-43.98M-45.82M-90.06M-70.1M-154.42M-81.76M-76.81M-70.58M-67.55M-97.4M-75.29M11.54M1.53M21.85M
FCF Margin %-8.77%-10.8%-13.73%-72.36%-134.4%-1529.35%-1079.9%-1454.44%-2707.52%-160.82%-405.39%-313.39%36.5%5.3%403.92%
FCF Growth %23.05%4.03%49.12%-28.48%54.6%-88.87%-6.44%-8.82%-4.5%30.65%-29.36%-752.4%652.84%-92.98%-
FCF per Share-0.15-0.18-0.19-0.41-0.44-1.48-0.91-1.19-1.26-1.42-2.43-3.290.620.111.64
FCF Conversion (FCF/Net Income)0.65x0.69x1.14x1.36x1.04x0.96x0.86x0.81x0.77x1.01x0.82x2.43x-4.17x-0.28x-2.25x
Interest Paid8.4M011.41M4.24M2.9M3.47M4.2M4.92M0000000
Taxes Paid489K0266K51K6K4K1K2K4K3K069K0160K0

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Regulatory reimbursement uncertainty

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Remains Highly Volatile

As reported in financial statements, Ardelyx's operating cash flow frequently diverges from net income, with OCF/NI ratios fluctuating wildly from 2.11 in 2024Q4 to -51.48 in 2025Q4, indicating that accounting accruals and non-cash adjustments significantly obscure the underlying cash-generating capacity of the core commercial business.

The extreme variance in the OCF/NI ratio suggests that reported net income is heavily influenced by non-operating items or timing differences in revenue recognition rather than consistent cash inflows. Investors should monitor whether this disconnect persists as the company attempts to scale its commercial footprint, as the current lack of alignment between earnings and cash flow complicates the assessment of true operational viability.

Free Cash Flow Remains Intermittently Negative

Based on recent SEC filings, Ardelyx's free cash flow trajectory is characterized by persistent deficits, with a cash burn of $32.3 million in 2026Q1 alone, highlighting the company's ongoing struggle to achieve self-sustaining operations despite the commercial launch of its primary therapeutic assets.

The inability to maintain positive free cash flow suggests that the current revenue ramp is insufficient to cover the high fixed costs associated with the company's specialized sales force. This trajectory implies that the business remains in a capital-intensive growth phase where cash outflows are likely to continue until market penetration reaches a critical threshold.

Working Capital Swings Impede Liquidity

According to quarterly data, working capital changes have been a significant source of volatility, ranging from a $18.9 million outflow in 2025Q2 to a $7.7 million inflow in 2025Q4, which suggests that inventory management and collection cycles are not yet optimized for stable cash flow generation.

These erratic swings in working capital indicate potential inefficiencies in managing channel inventory or delays in receiving payments from wholesalers and partners. Such instability warrants further investigation, as it may mask underlying challenges in the company's ability to convert product sales into actual cash on a predictable basis.

SBC Masks True Cash Burn

Data from recent financial disclosures reveals that stock-based compensation has consistently reached double-digit millions per quarter, peaking at $14.2 million in 2026Q1, which effectively obscures the true magnitude of the company's cash burn by inflating the operating cash flow figures through non-cash accounting adjustments.

While stock-based compensation is a standard tool for talent retention in biotechnology, its scale relative to the company's negative operating cash flow suggests that the actual economic cost of operations is higher than the headline cash flow metrics imply. Investors should consider the dilutive impact of this compensation strategy alongside the persistent cash deficits when evaluating the company's long-term funding requirements.

ARDX — Frequently Asked Questions

Quick answers to the most common questions about buying ARDX stock.

How much cash does Ardelyx, Inc. (ARDX) generate from operations?

Ardelyx, Inc. (ARDX) generated $-42.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Ardelyx, Inc.'s free cash flow?

Ardelyx, Inc. (ARDX) reported negative free cash flow of $44.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Ardelyx, Inc.'s capital expenditure (CapEx)?

Ardelyx, Inc. (ARDX) spent $1.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.